Firstly, welcome to SNT! As a holder of NEU and DXB I have been...

Firstly, welcome to SNT!

As a holder of NEU and DXB I have been a holder of companies that focused on Rare Diseases for over 10 years.

With Gary speaking at the American Society of Haematology, doctors, specialists and suffers will be keeping a close ear at our presentation, as our drug is compatible with Jax Inhibitors our product will compliment many approved treatments.

Pricing is a very interesting one, I was shocked to find out that NEU drug Daybue costs $500k pa. Insurance and Medicade cover most of the cost for the patients but by getting orphan drug designation, it’s the way the US govt. promotes pharmaceutical companies to develop drugs for these rare diseases. Without being able to charge such high amounts, companies wouldn’t bother spending and developing drugs for such small markets and sufferers would be out in the cold.

I personally don’t see us going to market alone, another TO/partner would be the way we enter these markets! But I can say we’d be roughly $150k+++ pa.

For Australia and Canada, being smaller markets my experience has shown me that normally you’d focus on the FDA approval, watch the money come in then expand to new regions.

Also another example is DXB where they’ve licensed their drug to different markets to other pharmaceutical companies and they will run lead on approval in markets they own the license too! So potentially in their case they would have the drug approved in 4 regions at once.

SNT is still in its early stages with about 2-3 years to go til we reach our true potential, but by getting in at this stage, this could be a retirement fund!